Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) SHH
Currency In CNY
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In CNY
Sector
Healthcare
Industry
Biotechnology
Employees
867
First IPO Date
January 23, 2020
| Name | Title | Pay | Year Born |
| Jisheng Wu | Director & Deputy GM | 0 | 1965 |
| Zelin Sheng | Chairman of the Board & GM | 0 | 1960 |
| Binhua Lyu | Deputy GM, EVice President of Chemistry & Director | 0 | 1979 |
| Shice Shao | Accounting Supervisor | 0 | N/A |
| Zeqi Sheng | Chief Scientific Officer | 0 | 1964 |
| Gang Huang | Chief Financial Officer & Deputy GM | 0 | 1971 |
| Huiping Lu | Executive Vice President & Director | 0 | 1967 |
| Qingping Gao | Deputy GM & Board Secretary | 0 | 1977 |
Suzhou Zelgen Biopharmaceuticals Co., Ltd. is a Chinese company engaged in the entire lifecycle of pharmaceutical products, from research and development to manufacturing and sales, within the People's Republic of China. Their product portfolio encompasses both small molecule and recombinant protein-based drugs, which are developed to treat a variety of serious health conditions. These include several types of cancer such as liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, and nasopharyngeal carcinomas. Furthermore, the company's medications address myelofibrosis, hemorrhage, and various hepatobiliary diseases. The firm was established in 2009 and is headquartered in Kunshan, located within the People's Republic of China.